

資料 6

RECIST guidelines

Characteristic	RECIST
Measurability of lesions at baseline	<ol style="list-style-type: none"> <li>1. Measurable, unidimensional (LD only, size with conventional technique <math>\geq 20\text{mm}</math>; spiral computed tomography <math>\geq 10\text{mm}</math>)</li> <li>2. Nonmeasurable: all other lesions, including small lesions. Evaluable is not recommended</li> </ol>
Objective response	<ol style="list-style-type: none"> <li>1. Target lesions (change in sum of LDs, maximum of 5 per organ up to 10 total [more than one organ]) <ul style="list-style-type: none"> <li>CR: disappearance of all target lesions, confirmed at <math>\geq 4</math> wk</li> <li>PR: <math>\geq 30\%</math> decrease from baseline, confirmed at 4 wk</li> <li>PD: <math>\geq 20\%</math> increase over smallest sum observed, or appearance of new lesions</li> <li>SD: neither PR or PD criteria met</li> </ul> </li> <li>2. Nontarget lesions <ul style="list-style-type: none"> <li>CR: disappearance of all target lesions and normalization of tumor markers, confirmed at <math>\geq 4</math> wk</li> <li>PD: unequivocal progression of nontarget lesions, or appearance of new lesions</li> <li>Non-PD: persistence of one or more nontarget lesions and/or tumor markers above normal limits</li> </ul> </li> </ol>
Overall response	<ol style="list-style-type: none"> <li>1. Best response recorded in measurable disease from treatment start to disease progression or recurrence</li> <li>2. Non-PD in nontarget lesion(s) will reduce a CR in target lesion(s) to an overall PR</li> <li>3. Non-PD in nontarget lesion(s) will not reduce a PR in target lesion(s)</li> </ol>
Duration of response	<ol style="list-style-type: none"> <li>1. Overall CR <ul style="list-style-type: none"> <li>From: date CR criteria first met</li> <li>To: date recurrent disease first noted</li> </ul> </li> <li>2. Overall response <ul style="list-style-type: none"> <li>From: date CR or PR criteria first met (whichever status came first)</li> <li>To: date recurrent disease or PD first noted</li> </ul> </li> <li>3. SD <ul style="list-style-type: none"> <li>From: date of treatment start</li> <li>To: date PD first noted</li> </ul> </li> </ol>

RECIST = Response Evaluation Criteria in Solid Tumors, LD = longest diameter, CR = complete response, PR = partial response, PD = progressive disease, NC = no change, SD = stable disease.

Journal of the National Cancer Institute, Vol.92, No.3, February 2, 180, 2000